C4 Therapeutics (CCCC) to Release Earnings on Thursday

by · The Markets Daily

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 12:30 PM ET.

C4 Therapeutics Stock Performance

NASDAQ:CCCC opened at $2.30 on Tuesday. The company has a 50-day moving average of $2.04 and a 200-day moving average of $2.35. C4 Therapeutics has a 52 week low of $1.09 and a 52 week high of $3.65. The company has a market capitalization of $222.89 million, a price-to-earnings ratio of -1.38 and a beta of 2.96.

Institutional Trading of C4 Therapeutics

Several large investors have recently made changes to their positions in CCCC. Virtu Financial LLC bought a new position in shares of C4 Therapeutics in the fourth quarter valued at about $39,000. Invesco Ltd. increased its position in C4 Therapeutics by 39.9% in the 4th quarter. Invesco Ltd. now owns 268,350 shares of the company’s stock valued at $513,000 after acquiring an additional 76,530 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of C4 Therapeutics in the fourth quarter worth about $254,000. Man Group plc lifted its position in shares of C4 Therapeutics by 72.9% during the fourth quarter. Man Group plc now owns 156,098 shares of the company’s stock worth $298,000 after purchasing an additional 65,820 shares in the last quarter. Finally, Engineers Gate Manager LP grew its stake in shares of C4 Therapeutics by 49.9% during the fourth quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock valued at $47,000 after purchasing an additional 8,130 shares during the last quarter. Institutional investors own 78.81% of the company’s stock.

Analyst Ratings Changes

CCCC has been the subject of a number of analyst reports. Brookline Capital Acquisition raised their price target on shares of C4 Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Wednesday, January 21st. TD Cowen started coverage on C4 Therapeutics in a research report on Tuesday, December 2nd. They issued a “buy” rating on the stock. Finally, Barclays dropped their price objective on C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.80.

View Our Latest Research Report on C4 Therapeutics

C4 Therapeutics Company Profile

(Get Free Report)

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.

Read More